Open Nav

RHNanopharmacuticals, LLC

  • Izhar Hasan, RHNanopharmacuticals, LLC

Spark investors' interest in a low risk 505 b(2) pathway pre desi drug development opportunity

  • Date:Thursday, October 18
  • Time:2:00 PM - 2:15 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:RH/Nanopharma is a pharmaceutical research and development company dedicated to treating, preventing, slowing and reversing Osteoarthritis ad Rheumatoid arthritis. We are reintroducing a pre-DESI, proven anti-inflammatory/analgesic agent with a patented, micronized formulation, based on animal data. Salsalate has established equivalent clinical efficacy and enhanced safety profile (cardiac, renal and GI toxicity) compared to traditional NSAIDs. We have completed a Pe IND meeting using 505(b)(2) regulatory pathway for Osteoarthritis. Our plans for IND filing is in progress and we anticipate to submit pharmacokinetic data to FDA in next few months.
  • Company
  • Company HQ City:Monmouth Beach
  • Company HQ Country:United States
  • Company HQ State:New Jersey                 
  • CEO/Top Company Official:Joel Ross MD
  • Year Founded:2017
  • Main Therapeutic Focus:Inflammation
  • Lead Product in Development :Nanosal
  • Development Phase of Primary Product:Phase I
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :03
  • Previous and Current Investors:Angel investors
  • Total Amount Raised to Date, In All Rounds:$500 K +
Izhar Hasan
RHNanopharmacuticals, LLC